Prognosis in UC After First Biological

NCT05530122 · clinicaltrials.gov ↗

COMPLETED

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

BIOLOGICAL: infliximab, adalimumab, golimumab, vedolizumab, ustekinumab

Sponsor

Tampere University Hospital